A Phase I/II Study of the Combination of Oral Rigosertib and Azacitidine in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML)

被引：3
|
作者：
Navada, Shyamala C. [1 ]
Garcia-Manero, Guillermo [2 ]
Wilhelm, Francois [3 ]
Hearn, Katherine [2 ]
Odchimar-Reissig, Rosalie [1 ]
Demakos, Erin P. [1 ]
Alvarado, Yesid [2 ]
Daver, Naval [2 ]
DiNardo, Courtney D. [2 ]
Konopleva, Marina [2 ]
Borthakur, Gautam [2 ]
Azarnia, Nozar
Silverman, Lewis R. [1 ]
机构：
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Onconova Therapeut Inc, Newtown, PA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3252.3252
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studies
    Uwe Platzbecker
    Joerg Chromik
    Jan Krönke
    Hiroshi Handa
    Stephen Strickland
    Yasushi Miyazaki
    Martin Wermke
    Wataru Sakamoto
    Yoshifumi Tachibana
    Tillmann Taube
    Ulrich Germing
    [J]. BMC Cancer, 22
  • [42] Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in Down syndrome: Pathologic aspects
    Mast, K.
    Taub, J. W.
    Alonzo, T.
    Mosse, C.
    Gamis, A. S.
    Mathew, P.
    Jones, H.
    Hitzler, J.
    Head, D. R.
    [J]. LEUKEMIA RESEARCH, 2013, 37 : S89 - S90
  • [43] Comparison of Symptom Burden in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
    Williams, Loretta A.
    Ahaneku, Hycienth
    Cortes, Jorge E.
    Manero, Guillermo Garcia
    Kantarjian, Hagop M.
    Shi, Qiuling
    Lin, Huei-Kai
    Limaye, Achala R.
    Cleeland, Charles S.
    [J]. BLOOD, 2014, 124 (21)
  • [44] Evaluation of ON01910.Na In Patients with a Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study
    Silverman, Lewis R.
    Navada, Shyamala C.
    Odchimar-Reissig, Rosalie
    Najfeld, Vesna
    Ohnuma, Takao
    Wilhelm, Francois
    Reddy, E. Premkumar
    Holland, James F.
    [J]. BLOOD, 2010, 116 (21) : 1214 - 1214
  • [45] Lenalidomide and Risk of Acute Myeloid Leukemia (AML) Transformation Among Myelodysplastic Syndrome (MDS) Patients
    Rollison, Dana E.
    Shain, Kenneth H.
    Lee, Ji-Hyun
    Hampras, Shalaka S.
    Fulp, William
    Fisher, Kate
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    Xu, Qiang
    Knight, Robert D.
    List, Alan F.
    Dalton, William
    Komrokji, Rami
    [J]. BLOOD, 2014, 124 (21)
  • [46] Phase I study of UCN-01 and ara-C for patients with refractory or relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
    Cortes, J
    Plunkett, WK
    Estey, EH
    Keating, MJ
    Madden, T
    Sampath, D
    Faderl, S
    Beran, M
    Dancey, J
    Kantarjian, HM
    [J]. BLOOD, 2001, 98 (11) : 211B - 211B
  • [47] Phase I Study of the Combination of 5-Azacitidine Sequentially with High-Dose Lenalidomide in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
    Garcia-Manero, Guillermo
    Daver, Naval G.
    Borthakur, Gautam
    Konopleva, Marina
    Ravandi, Farhad
    Wierda, William G.
    Estrov, Zeev
    Faderl, Stefan
    Kadia, Tapan
    Rey, Kristy
    Cheung, Cora
    Kantajian, Hagop M.
    [J]. BLOOD, 2011, 118 (21) : 1122 - 1122
  • [48] BASOPHILIA IN PATIENTS WITH MYELODYSPLASIC SYNDROME (MDS)/ACUTE MYELOID LEUKEMIA (AML) WHO RESPOND TO TREATMENT WITH AZACITIDINE
    Calderon Lopez, M. T.
    Garcia Leon, N.
    Seri Merino, C.
    Sandoval Barreto, E.
    Otero Martinez, M. J.
    Matilla Garcia, A.
    [J]. HAEMATOLOGICA, 2019, 104 : 439 - 440
  • [49] Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML)
    Garcia-Manero, G.
    Yang, A. S.
    Klimek, V.
    Luger, S.
    Newsome, W. M.
    Berman, N.
    Patterson, T.
    Maroun, C.
    Li, Z.
    Ward, R.
    Martell, R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Truncation Products of Stromal Cell Derived Factor-1 (CXCL12) Quantified By Mass Spectrometry in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Treated with Rigosertib in a Phase I-II Study
    Roboz, John
    Navada, Shyamala C.
    Cho, Sool Yeon
    Petrone, Michael E.
    Fruchtman, Steven M.
    Silverman, Lewis R.
    [J]. BLOOD, 2018, 132
12345